FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1	OIVID APPR	OVAL								
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Sinskey Anthony J						2. Issuer Name and Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC [ MACK ]										ck all applica Director	able)	ng Person(s) to Issue		ner	
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201					04.	3. Date of Earliest Transaction (Month/Day/Year) 04/03/2012										below)	give title		Other (sp below)		
(Street) CAMBRIDGE MA 02139					. 4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Inc Line)	,					
(City)	(St		(Zip)	Dori	rotiv	, Co	ouri	tion A		irod F	Nion		of or B	onof	inially.	Owned					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/L					sactio			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transact Code (Ins		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			A) or	5. Amoun Securities Beneficia Owned Fo	s lly ollowing (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount	(A (D	or	Price	Reported Transacti (Instr. 3 a	on(s)			Instr. 4)	
Common	Stock		04/03/2012 P 7,142 A \$7 326,309 D							D											
Common	Stock			04/0	3/20	12				С		36,7	23	A	(1)	363	032	2 D			
Common	Stock			04/0	3/20	12				С		18,0	24	A	(2)	381	056		I I	By Wife	
			Table II - I										, or Be ble se			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exp	6. Date Exercisa Expiration Date (Month/Day/Year			7. Title and Ar of Securities Underlying D Security (Inst 4)		rivative	8. Price of Derivative Security (Instr. 5)	9. Number derivatives Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				(	Code	v	(A)	(D)	Dat Exe	te ercisable		piration te	Title	Nur	ount or nber of ares						
Series B Convertible Preferred Stock	(1)	04/03/2012			С			23,793		(1)		(1)	Common Stock	36	,723 <sup>(1)</sup>	\$0	0		D		
Series C Convertible Preferred Stock	(2)	04/03/2012			С			18,024		(2)		(2)	Common Stock	18	3,024	\$0	0		I	By Wife	

## **Explanation of Responses:**

- 1. Each share of Series B Convertible Preferred Stock automatically converted into approximately 1.5435 shares of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.
- 2. Each share of Series C Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.

/s/ Jeffrey A. Munsie, attorneyin-fact 04/05/2012

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.